Spectral Med Inc's stock surged by 3.65% in the latest trading session, reflecting growing investor confidence.
In the latest trading session, Spectral Med Inc (EDT.TO) saw a notable increase, closing at CA$1.42, up 3.65%. This rise comes amid significant developments that could be influencing investor sentiment and market dynamics.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 – C$1.51 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are responding positively to recent milestones in Spectral Med Inc's journey, especially regarding its PMA application and clinical trial results, which may signal a promising future for the company.
Spectral Med Inc Climbs 3.65% in One Day
The stock's market cap now stands at CA$416.65 million, reflecting increased investor interest and confidence.
Bull case
The recent submission of the PMA application for PMX to the U.S. FDA is a crucial step forward, potentially paving the way for commercialization and revenue generation. Positive trial results could enhance the company's credibility and attract further investment.
Bear case
Despite the positive movement, investors should stay cautious. The lack of immediate financial results and the risks associated with FDA approvals and clinical trials could impact future stock performance.
Advertisement
Recent Developments Fueling Growth
Spectral Med Inc's recent submission of the PMA application for PMX to the U.S. FDA marks a significant milestone for the company. This application could lead to the commercialization of PMX, which has shown promising results in clinical trials. Investors are optimistic about the potential for future revenue as the company navigates this critical phase.
Market Sentiment and Future Outlook
The stock's rise reflects a positive market sentiment, driven by the company's advancements in clinical research and regulatory processes. However, investors should remain vigilant, as the path to FDA approval is fraught with challenges. The company's financial health and ability to execute its plans will be key factors to monitor in the coming months. For further insights, check out Spectral Med Inc's stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
